Abstract

BackgroundWe examined if treatment with acetylsalicylic acid (ASA), non-steroid anti-inflammatory drugs (NSAID), or statins after acute coronary syndrome (ACS) are associated with decreased risk of depression. MethodThis register-based cohort study included all individuals with a first-time hospital admissions with an ACS diagnosis registered between January 2001 to December 2009 (N=91,842) and a comparable reference population without ACS (N=91,860). Information of ASA, NSAID, and statin use were retrieved from a national prescription register. The study population was followed for hospitalization with depression or receiving prescription of antidepressant medication for up to one year after ACS or study entry (early depression) or one to twelve years after ACS or study entry (late depression). ResultsASA use after ACS was associated with decreased risk of early depression with hazard ratios (HR) of 0.89 (95% confidence interval 0.85–0.93) but not with late depression 0.96 (0.90–1.01). The corresponding HRs for statin were 0.90 (0.86–0.94) and 0.86 (0.82–0.90). In the non-ACS population, statin use was not associated with neither early nor late depression (HRs 1.04 (0.96–1.12) and 1.00 (0.95–1.06)), while ASA was associated with increased risk of late (HR 1.09 (1.04–1.14)) but not early depression (HR 1.03 (0.97–1.09)). In both populations, NSAID use was associated with increased risk of late but not early depression. ConclusionUse of ASA or statins were associated with decreased risk of depression in ACS patients but not in individuals without ACS, while use of NSAID was associated with increased risk of late depression in both populations.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.